Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Conduit Pharmaceuticals Inc Market Cap
From what 0 stock analysts predict, the share price for Conduit Pharmaceuticals Inc (CDT) might decrease by 100% in the next year. This is based on a 12-month average estimation for CDT. Price targets go from $ to $. The majority of stock analysts believe CDT is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Conduit Pharmaceuticals Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Conduit Pharmaceuticals Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CDT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2023
Staff Count
7
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. David Joszef Tapolczay
Market Cap
$10.2M
In 2023, CDT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CDT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Conduit Pharmaceuticals has appointed Simon Fry to its Board of Directors, enhancing its leadership with his 30 years of experience in investment banking and asset management.
Why It Matters - The addition of Simon Fry to Conduit Pharmaceuticals' Board could enhance strategic decision-making and investor confidence, potentially driving stock performance and growth prospects.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Conduit Pharmaceuticals has received patent approval from the Japan Patent Office for AZD1656, a glucokinase activator aimed at treating various autoimmune disorders.
Why It Matters - The patent approval for AZD1656 enhances Conduit Pharmaceuticals' competitive position, potentially increasing its market value and attracting investment interest in autoimmune therapeutics.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Conduit Pharmaceuticals filed two new patent applications for its lead candidate AZD1656, a glucokinase activator targeting autoimmune disorders, enhancing its intellectual property portfolio.
Why It Matters - New patent filings for AZD1656 could enhance Conduit Pharmaceuticals' market position and competitive edge, potentially increasing future revenue and attracting investor interest.
Fri, 01 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Conduit Pharmaceuticals Inc. has restructured a $2.65 million loan with Nirland Limited and secured $1.2 million in new promissory notes, improving its balance sheet and liquidity.
Why It Matters - Conduit's financial restructuring improves liquidity and balance sheet strength, potentially leading to better investment stability and growth prospects.
Wed, 14 Aug 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - Conduit Pharmaceuticals (NASDAQ: CDT) shares rose after SEC filings revealed that Nirland Limited owns a 14.8% stake in the company.
Why It Matters - Nirland Limited's 14.8% stake in Conduit Pharmaceuticals signals strong institutional interest, potentially boosting investor confidence and driving stock prices higher.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Conduit Pharmaceuticals plans to start Phase 2a trials for AZD1656 in treating systemic lupus erythematosus and ANCA-associated vasculitis, leveraging its safety profile from diabetes development.
Why It Matters - Conduit Pharmaceuticals' Phase 2a trials for AZD1656 in autoimmune disorders could indicate potential revenue growth and market expansion, influencing stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
